Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference

Figures & data

Table 1 Patient baseline characteristics

Parameter	Value
Age (y)
Mean ± SD	49.8 ± 2.76
Range	23–75
Gender, n (%)
Male	10 (33.3)
Female	20 (66.7)
Severity of eye itch (1–5)
Mean ± SD	3.17 ± 0.16
Time of most severe eye itch, n (%)
AM	15 (50)
PM	13 (43.3)
Neither	2 (6.7)
Severity of itchy/runny nose (1–5)
Mean ± SD	3.3 ± 0.19
Time of most severe itchy/runny nose, n (%)
AM	17 (56.7)
PM	11 (36.7)
Neither	2 (6.7)
Satisfaction with OTC allergy eye drops, n (%)
Very satisfied	3 (10)
Some what satisfied	15 (50)
Not satisfied	11 (36.7)
Never tried	1 (3.6)
Duration of allergy symptoms, n (%)
Seasonal	16 (53.3)
Perennial	14 (46.7)
Time most outside, n (%)
AM	12 (40)
PM	18 (60)

Abbreviations: OTC, over the counter; SD, standard deviation.

Figure 1 (A) Morning and evening relief of ocular itch over 14 days of treatment (mean ± standard deviation). Ocular itch was graded on a 1–5 scale, with 5 being completely relieved. *P = 0.011 versus bepotastine besilate 1.5% in the evening; ^†P < 0.0001 versus olopatadine hydrochloride 0.2% in the morning. (B) Patient preference for all-day relief of ocular itching at study end (visit 3, day 35).

Notes: Each bar represents the number of patients who stated that the medication was superior. *P = 0.04.
Abbreviation: SD, standard deviation.

Figure 2 (A) Morning and evening relief of itchy/runny nose over 14 days of treatment (mean ± standard deviation). Nasal symptoms were graded on a 1–5 scale, with 5 being completely relieved. *P < 0.0001 versus bepotastine besilate 1.5% in the morning; **P < 0.0001 versus bepotastine besilate 1.5% in the evening; ^†P = 0.035 versus bepotastine besilate 1.5% in the morning. (B) Patient preference for all-day relief of itchy/runny nose at study end (visit 3, day 35).

Notes: Each bar represents the number of patients who stated that the medication was superior. *P = 0.01.

Figure 3 (A) Evening eye drop comfort over 14 days of treatment (mean ± standard deviation). Eye drop comfort was graded on a 1–5 scale, with 5 being very comfortable. (B) Patient preference for eye drop comfort at study end (visit 3, day 35).

Note: Each bar represents the number of patients who stated that the medication was superior.

Figure 4 Morning and afternoon/evening relief of overall ocular allergy symptoms over 14 days of treatment (mean ± standard deviation).

Notes: Overall ocular allergy symptoms graded on a 1–3 scale, with 3 being completely relieved. Ocular allergy symptoms included ocular itch, epiphora, conjunctival chemosis, hyperemia, and eyelid edema. *P = 0.032 versus bepotastine besilate 1.5% in the morning; **P < 0.0001 versus bepotastine besilate 1.5% in the evening; ^†P < 0.001 versus olopatadine hydrochloride 0.2% in the morning.

Figure 5 Overall patient preference for next prescription to treat allergic conjunctivitis at study end (visit 3, day 35). *P = 0.01.